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Abstract
Purpose The landscape of HER2+ metastatic breast cancer (mBC) treatment is changing due to the availability of new anti-
HER2 drugs. The purpose of this study was to assess the current treatment patterns and sequences used in HER2+ mBC in 
the real-world setting. Secondary objectives were to describe the factors that influence the decision to prescribe a first and 
second-line antitumour treatment.
Methods Retrospective chart review of 3068 cases in Spain, Italy, the Netherlands and the UK.
Results First and second-line treatments and regimens are consistent with the clinical guidelines, especially for recently 
initiated treatments. Age and performance status (PS) of patients impact treatment patterns: younger patients received more 
innovative treatments than elderly patients. In addition, while most patients received a first antitumor treatment, the rate of 
patients who continue to subsequent lines of therapy is low (55% transitioning from 1st to 2nd line; 58% from 2nd to 3rd 
line). Age and PS are key factors in the decision to prescribe further antitumor treatment.
Conclusion Fewer HER2+ mBC patients than expected receive a second and third line therapy. Guidelines should make 
specific recommendations for older patients or those with a poor PS.
Keywords HER2+ metastatic breast cancer · Treatment patterns · Treatment rates · Antitumour treatment
Introduction
An estimated 463,800 new cases of BC were reported in 
2012 in Europe, making it the leading cancer in women. In 
2012, the estimated age-standardised rates of BC incidence 
(per 100,000) were 94.2 in Europe overall, 84.9 in Spain, 
118 in Italy, 129.2 in the UK and 131.3 in the Netherlands 
[1]. The corresponding 2012 age-standardised mortality 
rates (per 100,000) reported were 23.1 in Europe overall, 
and 16.7 in Spain, 22.9 in Italy, 24.8 in the UK and 26.0 in 
the Netherlands [1].
Over-expression or amplification of the human epider-
mal growth factor receptor 2 (HER2), present in 15–30% 
of breast cancers, has been associated with a more aggres-
sive clinical phenotype and a poor prognosis, although the 
introduction of anti-HER2 targeted therapies has consider-
ably improved outcomes for HER2+ cancers [2, 3]. Targeted 
therapies for HER2+ mBC nowadays include trastuzumab, 
pertuzumab, trastuzumab emtansine (T-DM1) and lapatinib 
[4].
The monoclonal antibody trastuzumab has been avail-
able for use in Europe in the metastatic setting intravenously 
since 2000 and subcutaneously since 2013. Pertuzumab is 
a monoclonal antibody, indicated in first-line therapy for 
mBC HER2+ patients since 2013. TDM-1 received market 
approval in 2013 for second-line therapy. It comprises two 
linked active components, combining anti-HER2 targeted 
therapy (trastuzumab) with the cytotoxic effect of the tubu-
lin inhibitor, emtansine (DM1). Lapatinib, an inhibitor of 
the intracellular tyrosine kinase domain of HER2, was first 
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used under a conditional European Marketing Authorisation 
(EMA) granted in 2008 and has had a full EMA since 2015 
for combined use with capecitabine. More recently, Lapat-
inib received the EMA for use among more specific HER2 
BC subpopulations: in combination with trastuzumab or an 
aromatase inhibitor.
Recent European guidelines recommend anti-HER2 
targeted therapy for all HER2+ mBC patients as early as 
the first metastatic treatment, provided there are no contra-
indications [4]. It can be administered alone or with chemo-
therapy or hormonal therapy in hormone-receptor-positive 
(HR+) cases. In the event of disease progression, continued 
blockade of the HER2 pathway with anti-HER2 therapy is 
recognised as a treatment option with the highest level of 
evidence. Current guidelines recommend the combination of 
trastuzumab and pertuzumab with docetaxel chemotherapy 
as first-line therapy, T-DM1-monotherapy as the second-line 
and trastuzumab combined with chemotherapy or the lapat-
inib/capecitabine combination as the third-line treatment [4].
The changing treatment landscape signifies more options 
for HER2+ mBC patients, though also rendering the deci-
sion process more complex for physicians. The purpose of 
the present analysis was to demystify this process by deter-
mining the treatment patterns used in HER2+ mBC in a real-
world setting. In addition, the aim was to describe factors 
likely to influence the choice of HER2+ mBC treatments.
Methods
An independent, retrospective, multicentre chart review 
was conducted among 204 oncologists between January 
and April 2016 in Italy (N = 70), Spain (N = 64), the UK 
(N = 53) and the Netherlands (N = 17). Eligibility criteria 
were as follows: hospital-based oncologists with antitumour 
drug treatment experience (conventional chemotherapy or 
targeted therapies) of HER2+ mBC. They must also have 
been managing at least ten of these patients at the time of 
enrolment (five in the Netherlands).
Physician enrolment was stratified to represent the differ-
ent hospital types involved in managing HER2+ mBC (uni-
versity and non-university hospitals, oncology centres and 
private hospitals), distributed over the different geographical 
regions by country.
Physicians were given the research documentation and 
received training regarding the target population, methods 
of data collection, definitions and safety reporting.
The chart review comprised cross-sectional and retro-
spective components, both requiring data to be documented 
retrospectively from treatment initiation (adjuvant if patient 
diagnosed at stage I-III) to the most recent treatment.
For the cross-sectional review, inclusion criteria included 
all female HER2+ mBC patients seen over a period of two 
to three weeks. The study excluded patients enrolled in a 
clinical trial or an early-access programme. Oncologists 
completed a questionnaire on the characteristics and treat-
ment history of 3068 patients (N = 1,270 in Italy, N = 957 
in Spain, N = 750 in the UK and N = 91 in the Netherlands).
For the retrospective review, each oncologist was asked to 
document eight patient cases that showed disease progres-
sion following the most recent treatment. Included in the 
study were female HER2+ mBC patients, alive or deceased, 
for whom oncologists had full access to the complete records 
from the treatment initiation date until either the end of the 
data extraction period or death. To ensure sufficient sample 
sizes in subsequent lines, specific quotas per line of therapy 
were applied: four patients with disease progression after the 
1st treatment, two with disease progression after the 2nd and 
two with disease progression after the 3rd treatment. Based 
on 1469 patients [Italy (N = 549); Spain (N = 434); the 
UK (N = 428); and the Netherlands (N = 58)], this review 
provided more detailed data on patient characteristics and 
treatments completed.
A different treatment given following a documented dis-
ease progression was considered “new.” The end of a treat-
ment was the time at which all therapeutic agents (including 
hormonal therapy) were withdrawn. If chemotherapy was 
discontinued prior to targeted therapy, the end of treatment 
corresponded to the end of the targeted therapy. A treat-
ment could comprise chemotherapy, targeted therapy and/
or hormonal treatment that could be initiated concomitantly 
or sequentially. For clarity, we will refer to ‘treatments’ and 
their ranking (1st, 2nd treatment, etc.) rather than ‘lines of 
treatment’. For example, hormonal treatment in combination 
with targeted therapy, initially given in the metastatic stage 
to a hormone-sensitive HER2+ mBC patient, is referred to 
as ‘1st treatment’, and the subsequent regimen combining 
chemotherapy and targeted therapy, following disease pro-
gression, is the ‘2nd treatment’.
Calculation of the treatment rates
The treatment rates were calculated from the cross-sectional 
review data. A two-level adjustment factor, based on consul-
tation frequency and treatment interval, was applied to the 
data. Indeed, the probability of being included in the cross-
sectional review was conditioned by these factors.
The first weighting factor thus takes into account the date 
of the next scheduled consultation, with a lower coefficient 
allocated to patients returning sooner.
The second weighting, based on the sequence intervals, 
considered the time elapsed since the beginning of a given 
step in the patient pathway, which can refer to a current treat-
ment, Supportive Care only (Sco), or a drug-free interval. 
However, comparing multiple patients at different steps of 
their pathways requires putting them all on the same time 
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reference, and the reality is that individual patients spend 
different amounts of time at different treatment stages. To 
neutralize this time factor in the case of a cross-sectional 
review, it was necessary to take into account the time elapsed 
since the beginning of the current treatment sequence for 
each of the following populations and compare with the 
mean duration of the 1st treatment:
• patients currently receiving 1st treatment.
• patients in the drug-free interval or receiving SCo after 
a 1st treatment.
• patients receiving a 2nd treatment.
• patients in the drug-free interval after the 2nd treatment.
Each population was weighted by dividing the baseline 
duration (here, time elapsed since start of the 1st treat-
ment) by the time elapsed since the beginning of the current 
treatment.
To calculate treatment rates from one treatment to the 
next— for example from 1st to the 2nd—the number of 
patients receiving a 2nd treatment was divided by the num-
ber of patients receiving a 1st treatment, and so forth. The 
rate of patients receiving a 2nd treatment would be calcu-
lated as
Statistical analyses
Z-tests were used to compare categorical variables (%), with 
a two-tailed probability threshold of 0.05 considered sig-
nificant. Student’s t test was used to compare quantitative 
variables (means), with a significance threshold of 0.05.
Logistic regression and decision trees1 were considered as 
multivariate analyses to rank the factors influencing the thera-
peutic choice of antitumour treatment or SCo instead of the 
1st and 2nd antitumour treatment regimen (1st, 2nd analysis, 
respectively). The decision trees were subsequently chosen.
In the 1st analysis, logistic regression and decision 
trees yielded similar accuracy (> 98%) and slightly greater 
specificity than the logistic regression (40 and 34%, respec-
tively) according to the confusion matrix. The area under the 
receiver operating characteristic (ROC) curve showed simi-
lar performance for both models (79 and 84%, respectively). 
Number of patients having received a 2nd treatment (currently receiving a 2nd treatment + in a drug − free interval or SCo after a 2nd treatment)
Number of patients having received a 1st treatment (currently receiving a 1st treatment + in a drug − free interval or SCo after a 1st treatment)
.
For the 2nd analysis, decision trees were retained due to 
a greater specificity than the logistic regression according 
to the confusion matrix (90% vs. 74%). Decision trees are 
easier to interpret, clearly portraying the decision algorithm 
a physician follows. Patient data were split for the decision 
trees: 70% to build the model and 30% to apply the model, 
test it and calculate the performance indicators.
For greater sample robustness, the data were consolidated 
at a European level.
Results
Description of the study populations 
across treatments
Of 3068 HER2+ mBC patients included in the cross-sec-
tional study, 66% were hormone-receptor positive (HR+), 
and 33% were hormone-receptor negative (HR−). Less than 
half the patients included were diagnosed at stages I to III 
(47 HR+, 46% HR−); 53 of HR+ and 54% of HR− patients 
were diagnosed at de novo stage IV.
Of 3068 patients, 2835 received a 1st treatment, 1226 
received a 2nd treatment and 551 received a 3rd treatment. 
Approximately half were under 60 years old. The majority 
of patients were HR+ (Table 1).
Table 1  Description of the study population who received a 1st, 2nd 
or 3rd treatment (TX)
HR+ hormone-positive tumour, HR− hormone-negative tumour
1st TX 2nd TX 3rd TX
N = 2835 (%) N = 1226 (%) N = 551 (%)
Age at start of treatment
 < 60 48 51 51
 60–70 30 34 32
 > 71 18 13 14
 Average (years) 59.5 58.8 59.1
 Median (years) 59.1 58.1 58.4
Hormonal status
 HR+ 65 62 59
 HR− 35 38 41
1 A decision tree is a classifier with a tree structure. It is the result of 
a multivariate analysis which consists of determining a sequence of 
nodes. A decision node specifies a significant test on an independent 
variable (predictor). A leaf node indicates the threshold for signifi-
cance of the variable, and divides the sample into two sub-samples. 
Decision trees classify instances by starting at the root of the tree and 
moving through it until a leaf node.
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Patterns of treatment and time elapsed 
since initiation
The results show that the first and second treatments initiated 
in the previous year were significantly different from those 
initiated over a year ago. The cross-sectional analysis shows 
that trastuzumab and pertuzumab with a taxane were the 
most widely used regimen for the 1st treatment for 36% of 
patients. This combination was more likely to have been ini-
tiated recently (≤ 12 months, for 45% of patients), whereas a 
regimen combining trastuzumab with a taxane (without per-
tuzumab) was more likely to have begun > 12 months ago.
Eleven percent of patients received hormonotherapy 
(HT) combined with targeted therapy (HT/TT) and without 
chemotherapy (CT). Hormone-based treatments were initi-
ated in more patients over the past 12 months compared 
to > 12 months.
T-DM1 alone was the most frequently prescribed 2nd 
treatment, for 36% of patients. T-DM1 alone was docu-
mented at higher rates (47%) among treatments initiated in 
the past 12 months, whereas higher rates of capecitabine/
lapatinib or trastuzumab/vinorelbine were seen among treat-
ments initiated over one year ago (Table 2).
T-DM1 was the 2nd treatment for 56% of patients, who 
received pertuzumab/trastuzumab/taxane as the 1st treat-
ment. On average, this treatment sequence was initiated 
16 months prior to inclusion in the research. In contrast, 
the capecitabine/lapatinib combination as a 2nd treatment 
was used most frequently (53%) after an initial regimen 
combining trastuzumab with a taxane as the 1st treatment, 
a sequence starting on average 20 months prior to inclusion 
in the research.
The regimens used as the 3rd treatment were mainly 
capecitabine/lapatinib (24% of patients), T-DM1 (23%) or 
trastuzumab plus chemotherapy (21%). The regimen given 
as the 3rd treatment largely depended on the previous treat-
ment: trastuzumab/chemotherapy was given first to patients 
who received T-DM1 as the 2nd treatment, whereas TDM-1 
was given mostly to those who received capecitabine/lapa-
tinib or trastuzumab/vinorelbine as a 2nd treatment. How-
ever, for the 2nd treatment, higher rates of TDM-1 were 
observed among treatments initiated in the last year (26% vs. 
Table 2  Regimen used for 1st, 2nd or 3rd treatment (current or completed) and as a function of time elapsed since start of treatment
CT chemotherapy, TT targeted therapy, HT hormonotherapy
* Value is significantly higher than the comparator group (p < 0.05)
TX regimen 1st TX 2nd Tx 3rd Tx
Total Time elapsed since TX initiation Total Time elapsed since TX initia-
tion
Total Time elapsed since TX 
initiation












CT and TT (no HT) 78 75 84* 45 36 66* 49 44 66
Docetaxel+trastuzumab+pe
rtuzumab
29 36* 21 2 2 1
Paclitaxel+trastuzumab 15 9 23* 3 3 5




Vinorelbine+trastuzumab 4 4 5 11 7 18* 14 11 22*
Capecitabine+trastuzumab 3 3 2 5 4 6 7 6 9
Capecitabine+lapatinib 2 2 3 20 16 29* 24 23 30
Docetaxel+pertuzumab 1 1* < 1
HT and TT (no CT) 11 13* 8 6 5 8* 4 5 3
Trastuzumab+non-steroidal 
AI
8 9* 4 3 3 2
Lapatinib+non-steroidal AI 1 2* 1 1 1 1
Trastuzumab+steroidal AI 1 1 1
TT only 5 6* 3 40 51* 20 28 31* 18
trastuzumab 2 2* 1 1 2 2 1
T-DM1 2 3* 1 36 47* 18 23 26* 13
Trastuzumab+pertuzumab 1 2* 1
Trastuzumab+lapatinib 1 1 1 4 3 4
CT only 3 4 3 8 8 6 18 20* 12
Other 3 2 2* < 1 < 1 0 1
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13%), whereas trastuzumab/chemotherapy prevailed among 
treatments initiated more than a year ago (31% vs. 17%).
Patterns of treatment and patient characteristics
Patient characteristics also influenced the treatments started 
in the past 12 months. Age had a significant impact on the 
1st treatment initiated in the past 12  months. Younger 
patients were more likely to receive a 1st treatment regi-
men including pertuzumab combined with trastuzumab 
and a taxane, whereas regimens combining trastuzumab 
and vinorelbine/capecitabine were more frequent in older 
patients (Table 3). The combination of hormonal treatment 
with a TT (trastuzumab or lapatinib, no chemotherapy) was 
more frequent in patients older than 70. The 1st treatment 
differed with the patient’s performance score: administration 
rates of the trastuzumab/pertuzumab/taxane regimen were 
higher among patients with ECOG scores of 0 or 1, whereas 
the trastuzumab/vinorelbine, vinorelbine/capecitabine, and 
HT/TT combinations were more frequently associated with 
ECOG ≥ 2 (Table 3). Usage rates for the 1st treatment also 
depended on the burden of metastases. Thus, the regimen 
combining pertuzumab, trastuzumab and docetaxel was 
sparingly given to patients with cerebral metastases, whereas 
the combination of HT with TT was less frequently given 
to patients with bone metastases only. As expected, these 
HT+ TT regimens were mainly used in HR+ patients (24% 
vs. < 1% received by HR− patients, p < 0.05). Second treat-
ment regimens differed according to age, PS, location of 
metastases and hormonal status (Table 4). T-DM1 was more 
frequently used in younger patients, whereas single-agent 
chemotherapies (e.g. capecitabine, vinorelbine, etc.) or a 
combination of HT and TT (no chemotherapy) were more 
common in patients older than 70 years. T-DM1 was more 
likely to be used in patients with a favourable ECOG score 
while the trastuzumab/vinorelbine combination or chemo-
therapy alone tended to be reserved for patients with higher 
ECOG scores. TDM-1 was less frequently used in patients 
with cerebral metastases; the capecitabine/lapatinib combi-
nation was the more likely treatment for this group. Lastly, 
T-DM1 was more often used for HR− cases than HR+ (59% 
vs 48%, p < 0.05).
Table 3  1st treatment regimen initiated in the past 12 months, as a function of the ECOG score, patient age and location of metastases
B bone, V ± B visceral ± bone, C ± , cerebral ± others, CT chemotherapy, TT targeted therapy, HT hormonotherapy, AI aromatase inhibitors
* Value is significantly higher than the comparator group
** Value is significantly lower than the comparator group
TOTAL Age ECOG Location of metastases
< 60 yrs 60–70 yrs > 70 yrs 0–1 2–4 B V ± B C±
N = 1648 (%) N = 770 (%) N = 509 (%) N = 369 (%) N = 1335 (%) N = 304 (%) N = 855 (%) N = 1298 (%) N = 160 (%)
CT and TT and no HT 75 83* 81 51** 78* 62 69** 81* 76
 Docetaxel+trastuzumab+p
ertuzumab
36 47* 40 12** 41* 17 35 39 28**
 Paclitaxel+trastuzumab 9 7 11 9 8 12 9 9 11
 Paclitaxel+trastuzumab+p
ertuzumab
9 10 8 6 10* 3 7 9 7
 Docetaxel+trastuzumab 6 6 6 5 6 6 5 7 9
 Vinorelbine+trastuzumab 4 2 2 7* 3 6* 4 4 3
 Capecitabine+trastuzumab 3 2 2 8* 2 8* 3 4 5
 Capecitabine+lapatinib 2 2 2 1 2 3 2 2 6*
 Docetaxel+pertuzumab 1 1 2 1 1 1 < 1** 2 2
HT and TT and no CT 13 6** 9** 33* 12 17* 20* 8** 9**
 Trastuzumab+non-steroi-
dal AI
9 3** 6** 26* 8 13* 14* 6** 5**
 Lapatinib+non-steroidal 
AI
2 1 1 4* 2 2 3* 1** 1
 Trastuzumab+steroidal AI 1 < 1 1 1 1 1 1 < 1 1
TT only 6 7 7 6 6 7 6 6 9
 T-DM1 3 3 3 1 3 2 1 3 6*
 Trastuzumab+pertuzumab 2 3 2 < 1** 2 1 2 2
 Trastuzumab 2 1 1 4* 1 4* 3 1 3
CT only 4 3 4 6 2 10* 4 4 6
CT and TT and HT 1 1 < 1 1 1 1 < 1 1 1
HT only 1 1 2* < 1 3* 1 < 1
CT and HT and no TT < 1 1 < 1 < 1 < 1
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Patient characteristics had less influence on the 3rd treat-
ment, although some of the trends observed for the 2nd treat-
ment (e.g. age and metastatic burden for T-DM1, lapatinib 
and the HT+ TT combination) were also applicable.
Treatment rates and factors influencing treatment 
rates
The treatment rates extrapolated from the cross-sectional 
review show that 90% of the HER2+ mBC patients received 
a 1st treatment, while 10% received SCo (no antitumour 
treatment). Patients receiving a 1st treatment were younger, 
more likely to be diagnosed earlier and had more favour-
able performance scores than patients who received SCo 
(Table 5).
55% of the patients receiving a 1st treatment subsequently 
received a 2nd one. 45% received SCo, being on average 
older than those receiving a 2nd treatment, with less favour-
able ECOG scores and the presence of brain metastases. 
Lastly, 58% of patients who received a 2nd treatment sub-
sequently received a 3rd. The factors influencing initiation 
of SCo after completion of a 2nd treatment regimen were 
as follows: age, patient performance score and metastatic 
burden, although the latter was not statistically significant 
(Table 5).
The decision tree shows that administering a 1st treat-
ment regimen (versus SCo) was driven by three statistically 
significant factors (Fig. 1), the most important being age; 
94% of patients ≤ 75 years received treatment vs. 53% of 
patients aged 76 or older. The subsequent factor was the 
performance score. Patients with an ECOG ≤ 2 were more 
likely to receive a 1st treatment: 96% of ≤ 75 years and 67% 
of > 75 years. Lastly, metastatic burden was a deciding fac-
tor for the older patient group with an ECOG ≤ 2: those with 
no brain metastases were more likely to receive treatment.
Conversely, the choice between a 2nd treatment and SCo 
was determined by the PS rather than by patients’ age.
Discussion
This study provides insight into the Real-World pattern 
of treatments received and factors influencing treatment 
choices for HER2+ mBC patients. Despite the broad inclu-
sion criteria, patients enrolled in a clinical trial or an early-
access programme at the time of study documentation 
were not included in the review, potentially representing a 
limitation concerning selection and patient characteristics. 
Nevertheless, patient clinical profiles were consistent with 
Table 4  Analysis of 2nd treatment initiated in the past 12 months as a function of the ECOG score, age of patients and location of metastases
B bone, V ± B visceral ± bone, C ±  cerebral ± others, CT chemotherapy, TT targeted therapy, HT hormonotherapy, AI aromatase inhibitors
* Value is significantly higher than the comparator group
TOTAL Age ECOG Location of metastases
< 60 yrs 60–70 yrs > 70 yrs 0–1 2–4 B V ± B C ±
N = 801 (%) N = 406 (%) N = 297 (%) N = 98 (%) N = 633 (%) N = 162 (%) N = 449 (%) N = 697 (%) N = 146 (%)
TT only 51 53 52 40** 54* 38 53 53 42
 T-DM1 47 50 49 31** 51* 33 48 49 39**
 Trastuzumab 2 2 1 4 1 3 2 1 1
 Trastuzumab + lapatinib 1 < 1 2 4* 2 1 1 2
CT and TT and no HT 36 36 35 36 35 38 32 35 46*
 Capecitabine + lapatinib 16 16 17 10 16 13 13 15 25*
Vinorelbine + trastuzumab 7 8 5 11 6 11* 6 7 9
 Capecitabine+trastuzumab 4 4 4 2 3 6 4 3 3
 Paclitaxel+trastuzumab 3 2 2 5 2 5 3 3 2
 ++Docetaxel+trastuzuma
b+pertuzumab
2 2 1 1 2 2 1 4*
CT only 8 9 6 12* 6 18* 8 8 8
 Capecitabine 2 2 2 3 1 6* 3 2 1
 Vinorelbine 1 1 4* 1 3* 1 1 2
 CA/CE 1 2 < 1 1 1 1 1 1
HT and TT and no CT 5 2** 6 10* 5 5 7* 4 4
 Trastuzumab+non-steroi-
dal AI
3 1 3 7* 3 1 4 2 1
 Lapatinib+non-steroidal 
AI
1 < 1 1 1 < 1 3* 1 1 2
CT and TT and HT < 1 1 1 < 1 1 < 1
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those found in the SystHERs registry, a currently ongoing 
prospective study [5].
The cross-sectional analysis shows that 1st and 2nd treat-
ment strategies are generally consistent with the European 
guidelines for HER2+ mBC patients [4]. Although the most 
recent innovative treatments are not yet widely used, our 
analysis shows that the newly-recommended regimens—the 
combination of trastuzumab, pertuzumab, and docetaxel as 
the 1st treatment, or T-DM1 as the 2nd treatment—are more 
extensively used in treatments initiated in the recent year. 
This suggests that treatment strategies are experiencing a 
transition period, exemplified by the authorizations of pertu-
zumab and T-DM1 for use in HER2+ mBC in Europe 2013, 
then implemented into clinical practice a few years later. 
Overall, the process from regulatory authorisation to physi-
cians’ prescribing habits is usually lengthy, the average time 
from approval to full access estimated at 14.9–18 months 
[6]. Other authors have estimated a possible three years from 
Table 5  Patient profile 
receiving a 1st (2nd, 3rd, 
respectively) treatment versus 
patients receiving SCo
* Significant difference compared with comparator group, p < 0.05
1st TX SCo 2nd TX SCo 3rd TX SCo
N = 1485 (%) N = 229 (%) N = 624 (%) N = 66 (%) N = 308 (%) N = 34 (%)
Age at diagnosis
 Mean (years) 58.6 74* 58.3 70.1* 58.7 66.1*
 Median (years) 57.6 76 58.2 71.0 57.8 65.0
 > 70 years 22 71* 8 50* 8 41*
ECOG
 PS0−1 85* 35 85* 11 82* 12
 PS 2+ 14 65* 15 89* 18 88*
Stage at diagnosis
 Metastatic 52 70* 49 59 48 53
 Non-metastatic 48* 30 51 41 51 47
Location of metastases
 Bone only 21 29* 10 20* 8 14
 Visceral ± bone 68* 44 71* 45 66 52
 Cerebral ± others 7 26* 17 35* 23 34
Number of metastatic sites
 1 site 46* 39 27 28 24 22
 > site 52 60* 72 72 76 78
Hormonal status
 HR+ 67 78* 66 57 61 52
 HR− 32* 21 34 41 39 48
Fig. 1  Decision tree showing factors determining the physician’s decision to administer a 1st antitumour treatment regimen (TX) versus SCo, or 
b 2nd TX versus SCo
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market launch to clinical results in terms of improved sur-
vival [7].
Even when considering the treatments initiated over 
the past year, i.e. those which are closer to the latest Euro-
pean guidelines, results show that treatments were adapted 
to the patient’s clinical profile (age, PS, hormonal status) 
and extent of metastases. In the  1st treatment, taxane/trastu-
zumab/pertuzumab was generally used in younger patients 
with a more favourable performance score and with mildly 
aggressive disease, and less frequently among patients with 
cerebral metastases. The regimens combining trastuzumab 
with capecitabine or vinorelbine were associated with 
higher age and a less favourable performance score. The 
combination of HT with TT (without chemotherapy) was 
predominantly used in hormone-sensitive patients in older 
age groups with indolent disease (bone metastases only) or 
an unfavourable performance score. These results echo that 
of registHER, a prospective study done in the U.S. Like the 
present study, it concluded that elderly patients were more 
likely to receive hormonal therapy (alone or in combination) 
than their younger counterparts [8].
A 2nd treatment with T-DM1, as recommended by guide-
lines, was reported at higher rates in younger patients, those 
with more favourable performance scores, and those with-
out cerebral metastases. The cross-sectional analysis also 
showed that the transition rates from 1st treatment to 2nd 
and 2nd treatment to 3rd were relatively poor (55 and 58%). 
Just as physicians tailor treatments to patients’ age, PS and 
metastatic burden, the decision trees show that age (younger 
or older than 75) and performance scores are key factors in 
deciding to prescribe further antitumour treatment or select 
SCo. The question of discontinuing active anticancer drug 
therapy in favour of SCo remains crucial, yet physicians 
lack guidelines to assist their decision-making [9]. Further-
more, patient preferences, balancing quality and length of 
life, must be considered in this complex decision [10–12]. 
Nevertheless, age and PS considerations could be prevent-
ing certain patients from receiving the most recent and most 
innovative treatments tolerable.
Generally, consensus guidelines recommend that manage-
ment decisions should not be based on age alone in elderly 
patients with breast cancer [13, 14], but under-treatment 
resulting from adjustment of protocols to elderly populations 
has been reported [13]. Older adults are under-represented 
in clinical trials, particularly those over 75 years [15], and 
data come only from subgroup analysis [16–18]. Recent sub-
group analysis from phase III studies showed a good safety 
profile of the most recent targeted therapies (pertuzumab 
and T-DM1) for elderly patients [16, 18]. Nevertheless, there 
is still a paucity of data regarding the outcomes and toxic-
ity in elderly patients of treatments that are recommended 
for use in the general population [19]. The findings of the 
present analysis provide crucial real-world evidence on a 
European level relating to the actual treatment decisions in 
elderly patients with mBC.
Conclusion
This cross-sectional study shows that clinical guidelines 
for treatment patterns in HER2+ mBC are increasingly 
being followed in Europe. Furthermore, as observed in a 
real-world setting, the proportion of patients transitioning 
from one line of therapy to the next is lower than expected. 
However, the results highlight that patient’s clinical char-
acteristics (such as age, PS, and the extent and location of 
metastases) strongly influence the treatment choice in first 
and second-line, as well as the decision to either prescribe 
and continue with an active antitumor treatment or to change 
to SCo (Fig. 1). Consequently, this has a direct impact on 
the management of elderly patients with a poor PS who are 
undertreated and receive less innovative treatments. There-
fore, specific guidelines for this subpopulation are necessary.
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